Breaking News

Gilead’s Remdesivir Shows Promise in COVID-19

Antiviral drug being evaluated in two Phase III trials in patients with severe and moderate manifestations

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

According to a World Health Organization official, Gilead’s experimental antiviral drug remdesivir, to date, shows the most promise for treating COVID-19 disease. Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity. Although it is not currently approved for use, Remdesivir has demonstrated in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS, which are also coronaviruses and are structurally similar to COVID-19. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters